This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (173)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Incidence and Drug Etiology in France, 1981-1985

Jean-Claude Roujeau, MD; Jean-Claude Guillaume, MD; Jean-Paul Fabre, PhD; Dominique Penso, MD; Marie-Laure Fléchet, MD; Jean-Pierre Girre, MD

Arch Dermatol. 1990;126(1):37-42.

Abstract
• We looked retrospectively for all cases of toxic epidermal necrolysis that occurred in France over a 5-year period to appreciate the incidence of this disorder and its drug etiology. Of the 399 cases identified, we obtained detailed information on 344 cases and validated 253 cases. From response rates (66% to 98%), we estimated the actual total number of cases to be 333, and the incidence of toxic epidermal necrolysis in France to 1.2 cases per million per year. An independent estimation derived from death certificates gave a figure of 1.3 cases per million per year. When the number of cases with a given drug present were related to the defined daily doses of that drug sold over the 5-year period, the highest ratios were for sulfadiazin (230 · 10^-8), isoxicam (41 · 10^-8), oxyphenbutazone (18 · 10^-8), phenytoin (14 · 10^-8), fenbufen (13 · 10^-8), and cotrimoxazole (12 · 10^-8). This first nationwide study confirmed the rarity of toxic epidermal necrolysis. Within the two main classes of responsible drugs (antibacterial sulfonamides and nonsteroidal anti-inflammatory agents) the risks linked to different drugs appeared quite different, even for closely chemically related products.

(Arch Dermatol. 1990;126:37-42)

Author Affiliations
From the Service de Dermatologie, Hôpital Henri Mondor, Université Paris XII, Créteil, France (Drs Roujeau, Guillaume, Penso, and Fléchet), and Parke-Davis, Courbevoie, France (Drs Drs Fabre and Girre).

Footnotes
Accepted for publication July 21, 1989.

Presented in part at the Huitièmes Journées Françaises de Pharmacovigilance, Paris, France, October 1986.

Reprint requests to Service de Dermatologie, Hôpital Henri Mondor, 94010 Créteil, France (Dr Roujeau).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis
Levi et al.
Pediatrics 2009;123:e297-e304.
ABSTRACT | FULL TEXT  

36-Year-Old Man With Productive Cough and Diffuse Rash
Kumar et al.
Mayo Clin Proc. 2006;81:945-948.
FULL TEXT  

SEVERE CUTANEOUS REACTIONS TO SULFADOXINE-PYRIMETHAMINE AND TRIMETHOPRIM-SULFAMETHOXAZOLE IN BLANTYRE DISTRICT, MALAWI.
GIMNIG et al.
Am J Trop Med Hyg 2006;74:738-743.
ABSTRACT | FULL TEXT  

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
Mockenhaupt et al.
Neurology 2005;64:1134-1138.
ABSTRACT | FULL TEXT  

A Rare Case of Streptomycin-Induced Toxic Epidermal Necrolysis in a Patient with Tuberculosis: A Therapeutic Dilemma
Hmouda et al.
The Annals of Pharmacotherapy 2005;39:165-168.
ABSTRACT | FULL TEXT  

Possible Captopril-Induced Toxic Epidermal Necrolysis
Alkurtass and Al-Jazairi
The Annals of Pharmacotherapy 2003;37:380-383.
ABSTRACT | FULL TEXT  

Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases
Prins et al.
Arch Dermatol 2003;139:26-32.
ABSTRACT | FULL TEXT  

Cutaneous Drug Reactions
Svensson et al.
Pharmacol. Rev. 2001;53:357-379.
ABSTRACT | FULL TEXT  

Toxic Epidermal Necrolysis in Children--An Update
Ringheanu and Laude
CLIN PEDIATR 2000;39:687-694.
ABSTRACT  

Treatment of the Cutaneous Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Silver Nitrate-Impregnated Dressings
Lehrer-Bell et al.
Arch Dermatol 1998;134:877-879.
FULL TEXT  

Value of Epidemiologic Studies in Determining the True Incidence of Adverse Events: The Nonsteroidal Anti-inflammatory Drug Story
Miwa et al.
Arch Intern Med 1997;157:2129-2136.
ABSTRACT  

Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau et al.
NEJM 1995;333:1600-1608.
ABSTRACT | FULL TEXT  

Toxic Epidermal Necrolysis in Singapore, 1989 Through 1993: Incidence and Antecedent Drug Exposure
Chan
Arch Dermatol 1995;131:1212-1213.
ABSTRACT  

Characteristics of Toxic Epidermal Necrolysis in Patients Undergoing Long-term Glucocorticoid Therapy
Guibal et al.
Arch Dermatol 1995;131:669-672.
ABSTRACT  

Severe Adverse Cutaneous Reactions to Drugs
Roujeau and Stern
NEJM 1994;331:1272-1285.
FULL TEXT  

Adverse Cutaneous Reactions to Trimethoprim-Sulfamethoxazole in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis carinii Pneumonia
Roudier et al.
Arch Dermatol 1994;130:1383-1386.
ABSTRACT  

Cutaneous Disease and Drug Reactions in HIV Infection
Coopman et al.
NEJM 1993;328:1670-1674.
ABSTRACT | FULL TEXT  

Sudden Onset of Blisters and Ulcerations in a Healthy Man
Serfling et al.
Arch Dermatol 1993;129:779-780.
ABSTRACT  

A Population-Based Study of Stevens-Johnson Syndrome: Incidence and Antecedent Drug Exposures
Strom et al.
Arch Dermatol 1991;127:831-838.
ABSTRACT  

Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: An Epidemiologic Study From West Germany
Schopf et al.
Arch Dermatol 1991;127:839-842.
ABSTRACT  

Toxic Epidermal Necrolysis
Lacy
Nutr Clin Pract 1991;6:18-20.
ABSTRACT  

Incidence of Toxic Epidermal Necrolysis in Italy
Naldi et al.
Arch Dermatol 1990;126:1103-1104.
ABSTRACT